Related Experiment Video
Updated: Jan 30, 2026

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer
Huocong Huang1, Rolf A Brekken2,3
1Division of Surgical Oncology, Department of Surgery, and Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas.
Abstract:
The stroma of pancreatic ductal adenocarcinoma (PDA) forms a major barrier to therapy and immune surveillance. Elahi-Gedwillo and colleagues demonstrate that halofuginone has potent antifibrotic activity in PDA by directly inhibiting the activation of pancreatic stellate cells, thereby reducing the deposition of extracellular matrix components, including collagen and hyaluronic acid. As a result, halofuginone improves drug delivery and the infiltration of favorable immune cells such as immune-stimulatory myeloid cells and cytotoxic T cells. Despite recent controversies regarding targeting stroma in PDA, this study highlights that modifying the stroma of PDA remains an attractive strategy to improve the efficacy of therapy.See related article by Elahi-Gedwillo et al., p. 372.
Insights
Halofuginone reduces pancreatic cancer stroma by inhibiting pancreatic stellate cell activation. This improves drug delivery and immune cell infiltration, enhancing cancer therapy effectiveness.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Pancreatic ductal adenocarcinoma (PDA) stroma impedes therapy and immune surveillance.
- Pancreatic stellate cells (PSCs) drive PDA stroma formation through extracellular matrix (ECM) deposition.
- Targeting PDA stroma is a potential therapeutic strategy.
Purpose of the Study:
- To investigate the antifibrotic effects of halofuginone in PDA.
- To determine if halofuginone modulates PSC activation and ECM deposition.
- To assess the impact of halofuginone on drug delivery and immune cell infiltration in PDA.
Main Methods:
- In vitro studies on pancreatic stellate cells.
- Assessment of ECM component deposition (collagen, hyaluronic acid).
- Evaluation of drug delivery and immune cell infiltration in a PDA model.
Main Results:
- Halofuginone demonstrated potent antifibrotic activity by inhibiting PSC activation.
- Reduced deposition of collagen and hyaluronic acid was observed.
- Improved drug delivery and increased infiltration of immune-stimulatory myeloid cells and cytotoxic T cells were noted.
Conclusions:
- Halofuginone effectively reduces PDA stroma by inhibiting PSC activation.
- Stromal modification with halofuginone enhances anti-cancer immunity and therapeutic delivery.
- Targeting the tumor stroma remains a promising strategy for improving PDA treatment efficacy.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Protein Transport to the Stroma
Protein complexes called the translocon of the outer chloroplast membrane or TOC complex, and the translocon of the inner chloroplast membrane or TIC complex mediate the...
The Wave Nature of Light
Gene Therapy
Wave Parameters

